Case Report

J Rheum Dis 2012; 19(2): 91-94

Published online April 30, 2012

© Korean College of Rheumatology

A Case of Acute Myeloid Leukemia after Adalimumab Treatment in Psoriatic Arthritis

Hong Ki Min1, Jae Ho Lee1, Hae Min Lee1, Eunsil Koh1, Ju Yeon Heo1, Jun-Ki Min2, Sung Hwan Park1

Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea1, Seoul, Bucheon St. Mary's Hospital, School of Medicine, The Catholic University of Korea2, Bucheon, Korea

Correspondence to : Sung Hwan Park

Abstract

Hematologic malignancies and lymphoproliferative disorders have been reported after using tumor necrosis factor-a inhibitor in patients suffering from spondyloarthropathy. Previously reported cases were treated by using infliximab and etanercept. Usually, it takes approximately several months for leukemia or lymphoproliferative disorders to occur after the application of those agents. However, we report a case of acute myeloid leukemia that developed after short term usage of adalimumab in a patient suffering from psoriatic arthritis.

Keywords Psoriatic arthritis, Acute myeloid leukemia, Adalimumab

Article

Case Report

J Rheum Dis 2012; 19(2): 91-94

Published online April 30, 2012

Copyright © Korean College of Rheumatology.

A Case of Acute Myeloid Leukemia after Adalimumab Treatment in Psoriatic Arthritis

Hong Ki Min1, Jae Ho Lee1, Hae Min Lee1, Eunsil Koh1, Ju Yeon Heo1, Jun-Ki Min2, Sung Hwan Park1

Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, School of Medicine, The Catholic University of Korea1, Seoul, Bucheon St. Mary's Hospital, School of Medicine, The Catholic University of Korea2, Bucheon, Korea

Correspondence to:Sung Hwan Park

Abstract

Hematologic malignancies and lymphoproliferative disorders have been reported after using tumor necrosis factor-a inhibitor in patients suffering from spondyloarthropathy. Previously reported cases were treated by using infliximab and etanercept. Usually, it takes approximately several months for leukemia or lymphoproliferative disorders to occur after the application of those agents. However, we report a case of acute myeloid leukemia that developed after short term usage of adalimumab in a patient suffering from psoriatic arthritis.

Keywords: Psoriatic arthritis, Acute myeloid leukemia, Adalimumab

JRD
Jan 01, 2025 Vol.32 No.1, pp. 1~7
COVER PICTURE
Cumulative growth of rheumatology members and specialists (1980~2024). Cumulative distribution of the number of the (A) Korean College of Rheumatology members and (B) rheumatology specialists. (J Rheum Dis 2025;32:63-65)

Stats or Metrics

Share this article on

  • line

Related articles in JRD

Journal of Rheumatic Diseases

pISSN 2093-940X
eISSN 2233-4718
qr-code Download